Hello everyone,
Basel’s team is excited to announce that we are currently working on developing the RECIST 1.1 archetype. RECIST 1.1 (Response Evaluation Criteria in Solid Tumors) is a standardized set of criteria used by radiologists to assess changes in tumor size and response to treatment in clinical trials and clinical oncological routine. It is an essential tool for measuring tumor response and progression consistently.
While working on the RECIST 1.1 archetype, we decided it would also be beneficial to include the iRECIST criteria. iRECIST (immune-Response Evaluation Criteria in Solid Tumors) is an extension of RECIST 1.1 specifically designed to account for the unique patterns of response and progression observed with immunotherapy treatments. Although iRECIST shares most of its data items with RECIST 1.1, it differs in the way tumor response is represented.
We have created an initial archetype version, which you can view here.
We would greatly appreciate any comments, suggestions, or feedback from the community to help us improve and refine this archetype.
Thank you in advance for your support and contributions!